| Psoriasis vulgaris
Duobrii vs Otezla
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Duobrii vs Otezla with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOtezla has a higher rate of injection site reactions vs Duobrii based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Otezla but not Duobrii, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Duobrii
Otezla
At A Glance
Topical
Once daily
Corticosteroid/retinoid combination
Oral
Once or twice daily
PDE4 inhibitor
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Behcet Syndrome
Dosing
Psoriasis vulgaris Apply a thin layer once daily to affected areas, rubbing in gently; total dosage should not exceed approximately 50 g per week; avoid application on the face, groin, or axillae; do not use with occlusive dressings unless directed by a physician; discontinue when control is achieved.
Arthritis, Psoriatic, Psoriasis vulgaris, Behcet Syndrome Adults: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after 5-day titration starting at 10 mg; reduce to 30 mg once daily in severe renal impairment (OTEZLA XR not recommended in severe renal impairment).
Arthritis, Psoriatic, Psoriasis vulgaris (pediatric >=6 years) Weighing >=50 kg: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after weight-based titration; weighing 20 to <50 kg: OTEZLA 20 mg twice daily orally; reduce to once daily dosing in severe renal impairment.
Contraindications
- Pregnancy
- Known hypersensitivity to apremilast or to any of the excipients in the formulation
Adverse Reactions
Most common (>=1%) contact dermatitis, application site pain, folliculitis, skin atrophy, excoriation, rash, skin abrasion, skin exfoliation
Most common (>=2%) Diarrhea, nausea, headache, upper respiratory tract infection, vomiting, abdominal pain upper, nasopharyngitis
Serious Hypersensitivity, depression, weight decrease, severe worsening of psoriasis (rebound)
Pharmacology
Combination of halobetasol propionate, a synthetic corticosteroid that modulates cellular signaling, immune function, and inflammation, and tazarotene, a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds RAR-beta and RAR-gamma receptors to modify gene expression; precise mechanisms in plaque psoriasis are unknown.
Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP); PDE4 inhibition increases intracellular cAMP levels and reduces pro-inflammatory cytokines including IL-17, IL-22, and TNF-alpha in blood and skin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Duobrii
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Otezla
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (9/12)
UnitedHealthcare
Duobrii
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Otezla
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (2/8) · Qty limit (8/8)
Humana
Duobrii
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Otezla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Duobrii.
Cost estimate not availableAmgen Safety Net Foundation: Otezla
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DuobriiView full Duobrii profile
OtezlaView full Otezla profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.